« Return to News | Clinical Intelligence

Cellectis, Lonza reach milestone with CHO-K1SV GS

Friday, July 22, 2011 10:14 AM

Cellectis bioresearch and Lonza have reached a significant milestone in the development of a newly bioengineered cell line.

Using their proprietary meganuclease technology, Cellectis bioresearch successfully managed to deactivate ("knock-out") the cell-based glutamine synthetase (GS) in CHO-K1SV, Lonza's proprietary host cell line. This achievement comes as part of an overall strategic plan to further advance the GS Gene Expression System offering and is expected to contribute to shortened development timelines critical for the early phases of bioproduction.

Lonza's proprietary technology, the GS Gene Expression System, uses selection via glutamine metabolism to rapidly generate high-yielding and stable recombinant cell lines. Hundreds of cell lines using the GS System have already been created to generate therapeutic proteins for clinical trials and in-market supply. Removal of the cell-based GS activity will enable further improvements to be made to the selection process for creating highly productive recombinant cell lines.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.